Atlas Trials

Polycythemia Vera (PV)

18 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Polycythemia Vera (PV)

RecordFirmDate
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms (NCT06798805)IRCCS Azienda Ospedaliero-Universitaria di Bologna2022-02-15
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (NCT04243122)Ottawa Hospital Research Institute2021-02-17
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients (NCT04655092)PharmaEssentia Japan K.K.2021-01-19
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. (NCT05421104)Novartis Pharmaceuticals2020-11-27
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply (NCT04182100)PharmaEssentia Japan K.K.2019-12-20
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (NCT02577926)RWTH Aachen University2015-10-01
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms (NCT01816256)University Health Network, Toronto2013-05-01
Managed Access Programs for INC424, Ruxolitinib (NCT04745637)Novartis Pharmaceuticals

Track Polycythemia Vera (PV) automatically

Every clearance here is in the API, with alerts when new ones post.